Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 1/2023

THE NEWEST THERAPEUTICALLY APPROACH OF “DIABESITY” USING GLP-1 RA MOLECULES: IMPACT OF THE ORAL FORMULATION

MARIANA CORNELIA TILINCA 1,2#, CSILLA ANTAL 2#, ALINA BALINT 3#, ANDREEA SĂLCUDEAN 4*, ANDREEA VARGA 5

1Department of Internal Medicine I, “George Emil Palade” University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș, 540142, Romania
2 Department of Diabetology, Emergency County Hospital of Târgu Mureș, 540042, Romania
3 Department of Analytical Chemistry and Drug Analysis “George Emil Palade” University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș, 540142, Romania
4 Department of Ethics and Social Sciences, “George Emil Palade” University of Medicine, Pharmacy, Science, and
Technology of Târgu Mureș, 540142, Romania
5 Department of Family Medicine, “George Emil Palade” University of Medicine, Pharmacy, Science, and Technology of Târgu Mureș, 540142, Romania

Download Full Article PDF

Co-existing diabetes and obesity, frequently described by the term “diabesity”, is a major health problem associated with increased long-term complications and mortality. The management of “diabesity” could be challenging, because several antidiabetic drugs cause weight gain. Glucagon-like peptide receptor agonists (GLP-1 RAs) have been demonstrated to be effective agents for achieving glycaemic control in addition to reducing body weight in patients with type 2 diabetes. Oral semaglutide, the first oral formulation of a GLP-1 RA, is an important therapeutic option for individuals with a preference for oral therapy. This medication was created by co-formulating the semaglutide molecule with an absorption enhancer (SNAC) to overcome the difficulties of oral peptide administration. The introduction of an oral GLP-1 RA broadens the therapeutic choices for patients and represents an important milestone in the management of “diabesity”.